Late-onset CMV disease following CMV prophylaxis

Irish Journal of Medical Science

Volumn 178, Issue 3, 2009, Pages 333-336

  Donnelly, C ^a   Kennedy, F ^a   Keane, C ^a   Schaffer, K ^a   McCormick, P A ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Cytomegalovirus; Cytomegalovirus prophylaxis; Ganciclovir; Late onset cytomegalovirus; Liver transplant; Valganciclovir

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT;

AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS C; HIGH RISK PATIENT; HUMAN; INCIDENCE; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PROPHYLAXIS; TREATMENT OUTCOME; ADOLESCENT; ADULT; ANALOGS AND DERIVATIVES; CONFIDENCE INTERVAL; CYTOMEGALOVIRUS INFECTIONS; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CONFIDENCE INTERVALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 77249148433     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11845-009-0327-3     Document Type: Article

References (17)

1. Razonable RR, Emery VC (2004) Management of CMV infection and disease in transplant patients (Consensus article: International Herpes Management Forum management recommendations). Herpes 11:77-86
2. Patel R, Paya CV (1997) Infections in solid-organ transplant recipients. Clin Microbiol Rev 10:86-124
3. Hodson EM, Barclay PG, Craig JC, et al (2005) Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (Cochrane review). Cochrane Database Syst Rev 4:CD003774
4. Snydman DR (1999) Infection in solid organ transplantation. Transpl Infect Dis 1:21-28. doi:10.1034/j.1399-3062.1999. 10103.x
5. Baillie GM (2006) Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy. Am J Health Syst Pharm 63(Suppl 5):10-16. doi:10.2146/ ajhp060378
6. (2004) Cytomegalovirus. Am J Transplant 4(Suppl 10):51-58
7. Preiksaitis JK, Brennan DC, Fishman J et al (2005) Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5:218-227. doi:10.1111/j.1600- 6143.2004.00692.x (Pubitemid 40179508)
8. British Transplantation Society (2004) Guidelines for the prevention and management of cytomegalovirus disease after solid organ transplantation, 2nd edn. British Transplantation Society, London
9. McCormick PA, Kennedy F (2007) National liver unit liver transplant guidelines. St. Vincent's University Hospital, Dublin
10. McDevitt LM (2006) Etiology and impact of cytomegalovirus disease on solid organ transplant recipients. Am J Health Syst Pharm 63(Suppl 5):3-9. doi:10.2146/ajhp060377 (Pubitemid 44477465)
11. Singh N (2006) Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol 35:474-477. doi:10.1016/j.jcv. 2005.10.014
12. Limaye AP, Bakthavatsalam R, Kim HW et al (2006) Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81(12):1645-1652. doi: 10.1097/01.tp.0000226071. 12562.1a (Pubitemid 43948296)
13. De Gascun CF, Houlihan D, Coughlan S et al (2006) Cytomegalovirus infection in recipients of liver transplant in Ireland (abstract no. P753). Clin Microbiol Infect 12(Suppl 4)
14. Gane E, Saliba F, Valdecasas GJC et al (1997) Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 350:1729-1733. doi:10.1016/S0140-6736(97)05535-9 (Pubitemid 28036671)
15. Paya C, Humar A, Dominguez E et al (2004) Efficacy and safety of valganciclovir versus oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4:611-620. doi:10.1111/j.1600-6143.2004.00382.x (Pubitemid 38523584)
16. Arthurs SK, Eid AJ, PeDersen RA et al (2007) Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 13(12):1703-1709. doi:10.1002/lt.21280
17. Singh N (2006) Antiviral drugs for cytomegalovirus in transplant recipients: adVantages of preemptive therapy. Rev Med Virol 16:281-287. doi:10.1002/rmv.513 (Pubitemid 44497309)